Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rated “Moderate Buy” by Wall Street Analysts

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $5.83.

A number of research analysts have recently issued reports on the stock. Lake Street Capital dropped their price target on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Finally, Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th.

Insiders Place Their Bets

In other news, Director Eric Sachetta bought 37,537 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were acquired at an average price of $3.44 per share, for a total transaction of $129,127.28. Following the completion of the acquisition, the director directly owned 267,480 shares in the company, valued at approximately $920,131.20. This represents a 16.32% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have acquired a total of 120,171 shares of company stock worth $405,230 over the last ninety days. 10.20% of the stock is owned by company insiders.

Institutional Trading of Sensus Healthcare

A number of institutional investors have recently bought and sold shares of SRTS. EP Wealth Advisors LLC acquired a new stake in Sensus Healthcare during the 2nd quarter worth about $49,000. BlackRock Inc. acquired a new position in shares of Sensus Healthcare in the 2nd quarter valued at about $252,000. Bank of New York Mellon Corp acquired a new position in shares of Sensus Healthcare in the 2nd quarter valued at about $303,000. Finally, North Star Investment Management Corp. acquired a new position in shares of Sensus Healthcare in the 1st quarter valued at about $500,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Price Performance

Sensus Healthcare stock opened at $2.77 on Tuesday. The stock’s 50 day moving average is $3.09 and its 200 day moving average is $3.26. The firm has a market cap of $45.60 million, a P/E ratio of -2.95 and a beta of 1.18. Sensus Healthcare has a one year low of $2.66 and a one year high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

About Sensus Healthcare

Sensus Healthcare, Inc (NASDAQ: SRTS) develops and markets non-invasive medical devices for dermatology and oncology. The company’s primary focus is superficial radiation therapy, a low-energy X-ray treatment designed to treat conditions affecting or located near the surface of the skin.

Its product portfolio includes the SRT-100 system and related platforms, which are used primarily in the treatment of non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as keloid scars.